CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH This article presents a review and commentary of selected presentations from the all-virtual 62nd American Society of Hematology (ASH) Meeting and Exposition, which took place in December 2020. Coverage includes safety and efficacy results in trials of acalabrutinib, venetoclax, obinutuzumab, rituximab, LOXO-305, idelalisib, bendamustine, umbralisib, ublituximab, chlorambucil, lisocabtagene maraleucel, and others.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
